Skip to main content

Table 1 Studies with anti-HER2 molcules plus hormonal therapy in the first-line metastaic breast cancer

From: First-line therapy in HER2 positive metastatic breast cancer: is the mosaic fully completed or are we missing additional pieces?

Author N. of patients Treatment PFS (months) OS (months) Response Rate (%)
Kaufman et al. 2009 (TANDEM study) 207 Anastrozole 1 mg po daily + T iv (4 mg/kg loading dose, then 2 mg/kg weekly) 4.8 28.5 21
Anastrozole 1 mg po daily 2.4 (p = 0.002) 23.9 (p = 0.325) 7 (p = 0.018)
Huober et al. 2012 (ELECTRA) 92 Letrozole 2.5 mg po daily + T iv (4 mg/kg loading dose, then 2 mg/kg weekly) 14.1 NR 27
Letrozole 2.5 mg po daily 3.3 (p = 0.23) NR 13 (p = 0.002)
Johnston et al. 2009 (EGF30008) 263 Letrozole 2.5 mg po + Lapatinib 1500 mg po daily 8.2 33.3 28
Letrozole 2.5 mg po + placebo po daily 3.0 (p = 0.019) 32.3 (p = 0.113) 15 (p = 0.021)
  1. PFS progresson free survival, OS overall survival, T trastuzumab